people

Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…

6 months ago

Olympic Refuge Foundation unveils plans to step up support for millions of displaced people around the world with new strategy

03 June 2025 - The Olympic Refuge Foundation (ORF) Board met at Olympic House in Lausanne this week, to review the success of…

6 months ago

WinnerMining launches new energy power project.

Boston, Massachusetts, June 03, 2025 (GLOBE NEWSWIRE) -- With the changes of the times and the advancement of technology, people's…

6 months ago

Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO, TNQTech, honored with ‘India’s Top 50 CEOs, MDs, and Founders’ Recognition by the Great Manager Institute for 2025

MUMBAI, India, June 3, 2025 /PRNewswire/ -- Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO,…

6 months ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025 01:00 ET  | Source: argenx SE June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX),…

6 months ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare…

6 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

6 months ago

UnitedHealth Group Announces Earnings Release Date

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the…

6 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…

6 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

6 months ago